PAGB welcomes consultation on reclassification of Dovonex Psoriasis Ointment

Published on: 3 April 2017


PAGB supports Leo Laboratories Limited’s application to reclassify Dovonex Psoriasis 50 microgram/g Ointment (calcipotriol) and make it available over-the-counter in pharmacies in the UK.

Dovonex Ointment is an effective treatment for mild to moderate plaque psoriasis which has been previously diagnosed by a doctor in adults aged 18 years and over.  The Commission on Human Medicines has advised the Medicines and Healthcare products Agency (MHRA) that this product can be available as a Pharmacy medicine.

The MHRA is currently consulting on the proposal to reclassify Dovonex Ointment from a prescription only to a pharmacy medicine.  PAGB will be responding positively to the consultation.

John Smith, PAGB Chief Executive, comments:

“Over-the-counter availability offers people faster and easier access to effective medicines and reduces pressure and costs on GPs. Where a medicine can show it has a good safety profile and the condition it treats is suitable for self care, reclassification is very positive and should be encouraged.

“We support the reclassification of Dovonex Ointment which will offer fast and convenient access to this treatment for people with mild to moderate plaque psoriasis.  This is the most common form of psoriasis and once diagnosed by a doctor is well suited to management thorough self care.

“Pharmacists are highly-trained healthcare professionals with the skills and expertise to supply Dovonex Ointment appropriately and advise people with psoriasis about their condition.”

PAGB welcomes consultation on reclassification of Dovonex Psoriasis Ointment